Al Sandrock notches another post-Biogen role — and it's taking him right back onto familiar ground

John Carroll

Editor & Founder

Al Sandrock has landed another post-Biogen gig for this next chapter in his biotech career following the catastrophic collapse of his campaign for Aduhelm. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Al Sandrock notches another post-Biogen role — and it's taking him right back onto familiar ground

John Carroll

Editor & Founder

Sign up to read this article for free.

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Al San­drock notch­es an­oth­er post-Bio­gen role — and it's tak­ing him right back on­to fa­mil­iar ground

John Carroll

Editor & Founder

Sign up to read this article for free.

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Al Sandrock notches another post-Biogen role — and it's taking him right back onto familiar ground

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Avid Bioservices to be sold to private equity firms for $1.1B

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks